Jonas Söderling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jonas Söderling has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Johnny Ludvigsson
Division of Pediatrics, Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden
6 shared publications - Henrik Toft Sørensen
Department of Clinical Epidemiology, Center for Population Medicine, Aarhus University Hospital and Aarhus University, Denmark
5 shared publications - Ola Olén
Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
5 shared publications - Adrienne Gordon
Faculty of Medicine and Health, University of Sydney, Camperdown, Australia
4 shared publications Aimée E. van Dijk
Perined Utrecht The Netherlands
4 shared publications- Ayah Al Bizri
Department of Paediatrics, Mount Sinai Hospital, 600 University Avenue, Toronto, ON M5G 1X5, Canada
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Cumulative incidence of perianal manifestations in pediatric‐onset inflammatory bowel disease: A nationwide Swedish cohort study
Perianal disease is a recognized complication of pediatric Crohn's disease (CD), but data on ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD‐U) are limited. We examined the occurrence of perianal disease before, at, and after diagnosis of pediatric‐onset IBD compared with matched (age, sex, and geographical region) population comparators. Using Swedish nationwide registers, we identified 3501 children with CD, 3821 with UC, and 1081 with IBD‐U diagnosed 1990 to 2019, and 81,861 matched IBD‐free individuals. The 10‐year cumulative incidence of perianal disease was 24.8% in CD, 13.4% in IBD‐U, and 7.4% in UC, compared with 1.1% in comparators. Fistula incidences were 18.1%, 7.1%, 2.9%, and 0.3%. Perianal disease was associated with subsequent diagnostic reclassification, particularly from UC and IBD‐U to CD. Perianal disease is common in pediatric CD and occurs substantially more often in UC and IBD‐U than in the general population, highlighting its clinical relevance across pediatric IBD subtypes.
- 2 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessCumulative incidence of perianal manifestations in pediatric‐onset inflammatory bowel disease: A nationwide Swedish cohort study
Perianal disease is a recognized complication of pediatric Crohn's disease (CD), but data on ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD‐U) are limited. We examined the occurrence of perianal disease before, at, and after diagnosis of pediatric‐onset IBD compared with matched (age, sex, and geographical region) population comparators. Using Swedish nationwide registers, we identified 3501 children with CD, 3821 with UC, and 1081 with IBD‐U diagnosed 1990 to 2019, and 81,861 matched IBD‐free individuals. The 10‐year cumulative incidence of perianal disease was 24.8% in CD, 13.4% in IBD‐U, and 7.4% in UC, compared with 1.1% in comparators. Fistula incidences were 18.1%, 7.1%, 2.9%, and 0.3%. Perianal disease was associated with subsequent diagnostic reclassification, particularly from UC and IBD‐U to CD. Perianal disease is common in pediatric CD and occurs substantially more often in UC and IBD‐U than in the general population, highlighting its clinical relevance across pediatric IBD subtypes.
- 6 October 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Early Colectomy and Long-Term Risk of Cardiometabolic Disease in Ulcerative Colitis: A Nationwide Cohort Study
INTRODUCTION: Ulcerative colitis (UC) is characterized by chronic gastrointestinal inflammation often requiring corticosteroids, both of which may increase long-term cardiometabolic risk. Early colectomy may mitigate this risk by eliminating these exposures although data are limited. METHODS: We performed a matched cohort study using the Swedish National Patient Register and ESPRESSO histopathology cohort, identifying individuals aged 18 years or older with incident UC (2006–2021, follow-up through 2023). Patients who underwent total colectomy within 2 years of diagnosis (early colectomy) were matched 1:1 to those without early colectomy using propensity score matching. Primary outcome was incident cardiovascular disease (CVD), with type 2 diabetes mellitus (DM2) assessed as a secondary outcome. Kaplan-Meier analysis and Cox proportional hazards models were used for analyses. RESULTS: Among 1,832 individuals (median age 45 years, 64.6% men, and median postmatching follow-up of 9 years), early colectomy was associated with a significantly lower cumulative incidence of CVD on unadjusted Kaplan-Meier analysis ( P = 0.02). The CVD incidence rate was 9.1 per 1,000 person-years in the early colectomy group vs 13.0 in controls; after adjustment for baseline covariates, early colectomy was associated with a 32% lower risk of CVD, although this did not reach statistical significance (adjusted hazard ratio 0.68, 95% confidence interval 0.44–1.06). A numerically lower risk of DM2 was also observed (incidence rate: 5.5 vs 5.8 per 1,000 person-years; adjusted hazard ratio 0.76, 95% confidence interval 0.39–1.48); findings were consistent across sensitivity analyses. DISCUSSION: Early colectomy was associated with numerically lower risks of CVD and DM2 in UC, raising the possibility that earlier surgical intervention may mitigate long-term cardiometabolic risk beyond established inflammatory bowel disease-related benefits, although confirmation in larger studies is needed.
- 6 October 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Early Colectomy and Long-Term Risk of Cardiometabolic Disease in Ulcerative Colitis: A Nationwide Cohort Study
INTRODUCTION: Ulcerative colitis (UC) is characterized by chronic gastrointestinal inflammation often requiring corticosteroids, both of which may increase long-term cardiometabolic risk. Early colectomy may mitigate this risk by eliminating these exposures although data are limited. METHODS: We performed a matched cohort study using the Swedish National Patient Register and ESPRESSO histopathology cohort, identifying individuals aged 18 years or older with incident UC (2006–2021, follow-up through 2023). Patients who underwent total colectomy within 2 years of diagnosis (early colectomy) were matched 1:1 to those without early colectomy using propensity score matching. Primary outcome was incident cardiovascular disease (CVD), with type 2 diabetes mellitus (DM2) assessed as a secondary outcome. Kaplan-Meier analysis and Cox proportional hazards models were used for analyses. RESULTS: Among 1,832 individuals (median age 45 years, 64.6% men, and median postmatching follow-up of 9 years), early colectomy was associated with a significantly lower cumulative incidence of CVD on unadjusted Kaplan-Meier analysis ( P = 0.02). The CVD incidence rate was 9.1 per 1,000 person-years in the early colectomy group vs 13.0 in controls; after adjustment for baseline covariates, early colectomy was associated with a 32% lower risk of CVD, although this did not reach statistical significance (adjusted hazard ratio 0.68, 95% confidence interval 0.44–1.06). A numerically lower risk of DM2 was also observed (incidence rate: 5.5 vs 5.8 per 1,000 person-years; adjusted hazard ratio 0.76, 95% confidence interval 0.39–1.48); findings were consistent across sensitivity analyses. DISCUSSION: Early colectomy was associated with numerically lower risks of CVD and DM2 in UC, raising the possibility that earlier surgical intervention may mitigate long-term cardiometabolic risk beyond established inflammatory bowel disease-related benefits, although confirmation in larger studies is needed.
- 1 September 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (9) , 1232-1243
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy
There are concerns about a possible link between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and nonarteritic anterior ischemic optic neuropathy (NAION). To examine whether use of GLP-1RAs increases risk for AION, which predominantly comprises NAION. Nationwide, register-based, cohort study. Sweden, 2013 to 2024. Initiators of GLP-1RAs compared with initiators of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Anterior ischemic optic neuropathy in the national patient register. Adjusted risk differences (RDs) and risk ratios (RRs) were estimated using propensity score weighting. Median follow-up was 1.6 years (IQR, 0.7 to 3.1 years) for GLP-1RA users and 1.5 years (IQR, 0.7 to 2.9 years) for SGLT-2 inhibitor users. Sixty-two of 107 518 GLP-1RA users and 64 of 185 898 SGLT-2 inhibitor users experienced AION. Risks were 0.04% versus 0.02% (RD, 0.02% [95% CI, 0.00% to 0.03%]; RR, 1.93 [CI, 1.00 to 3.73]) at 1 year and 0.12% versus 0.07% (RD, 0.05% [CI, 0.00% to 0.10%]; RR, 1.69 [CI, 0.95 to 3.01]) at 5 years. The differences were substantially attenuated in analyses restricted to patients receiving metformin at baseline (1 year: RD, 0.01% [CI, -0.01% to 0.02%]; RR, 1.40 [CI, 0.64 to 3.05]; 3 years: RD, 0.01% [CI, -0.02% to 0.04%]; RR, 1.24 [CI, 0.68 to 2.26]; 5 years: RD, 0.02% [CI, -0.04% to 0.08%]; RR, 1.23 [CI, 0.65 to 2.33]). Few outcome events, unmeasured confounding, and limited generalizability to GLP-1RA users without diabetes. The relative risk for AION was higher with GLP-1RA use compared with SGLT-2 inhibitor use in type 2 diabetes. However, absolute risks were small, and the RDs were substantially reduced in analyses restricted to patients receiving metformin to better account for confounding by diabetes severity, suggesting observed increases in risk may reflect residual confounding. Karolinska Institutet, Swedish Society of Medicine, Swedish Research Council, and Region Stockholm.
- 1 September 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (9) , 1232-1243
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy
There are concerns about a possible link between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and nonarteritic anterior ischemic optic neuropathy (NAION). To examine whether use of GLP-1RAs increases risk for AION, which predominantly comprises NAION. Nationwide, register-based, cohort study. Sweden, 2013 to 2024. Initiators of GLP-1RAs compared with initiators of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Anterior ischemic optic neuropathy in the national patient register. Adjusted risk differences (RDs) and risk ratios (RRs) were estimated using propensity score weighting. Median follow-up was 1.6 years (IQR, 0.7 to 3.1 years) for GLP-1RA users and 1.5 years (IQR, 0.7 to 2.9 years) for SGLT-2 inhibitor users. Sixty-two of 107 518 GLP-1RA users and 64 of 185 898 SGLT-2 inhibitor users experienced AION. Risks were 0.04% versus 0.02% (RD, 0.02% [95% CI, 0.00% to 0.03%]; RR, 1.93 [CI, 1.00 to 3.73]) at 1 year and 0.12% versus 0.07% (RD, 0.05% [CI, 0.00% to 0.10%]; RR, 1.69 [CI, 0.95 to 3.01]) at 5 years. The differences were substantially attenuated in analyses restricted to patients receiving metformin at baseline (1 year: RD, 0.01% [CI, -0.01% to 0.02%]; RR, 1.40 [CI, 0.64 to 3.05]; 3 years: RD, 0.01% [CI, -0.02% to 0.04%]; RR, 1.24 [CI, 0.68 to 2.26]; 5 years: RD, 0.02% [CI, -0.04% to 0.08%]; RR, 1.23 [CI, 0.65 to 2.33]). Few outcome events, unmeasured confounding, and limited generalizability to GLP-1RA users without diabetes. The relative risk for AION was higher with GLP-1RA use compared with SGLT-2 inhibitor use in type 2 diabetes. However, absolute risks were small, and the RDs were substantially reduced in analyses restricted to patients receiving metformin to better account for confounding by diabetes severity, suggesting observed increases in risk may reflect residual confounding. Karolinska Institutet, Swedish Society of Medicine, Swedish Research Council, and Region Stockholm.
- Open Access
- 26 August 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Absolute Risk of Malignancy by Treatment in Patients With Crohn's Disease Compared with the General Population: A Nationwide Population-Based Cohort Study
INTRODUCTION: Real-world data quantifying absolute cancer risk in Crohn's disease (CD) by treatment status are lacking but are essential for patient counselling. METHODS: We linked nationwide Swedish register data and assessed incident cancers overall and by type in patients with CD 2007–2023. We estimated age-stratified incidence rate (IR) differences compared with the general population in a once-exposed-always-exposed design. Treatment cohorts comprised new users of thiopurine, tumor necrosis factor inhibitors (TNFi), thiopurine + TNFi, vedolizumab, ustekinumab, and patients naïve to immunomodulatory drugs. RESULTS: We followed 38,733 patients and 360,616 comparator subjects for a median 7.3 years. The IR differences for any cancer (number of excess cancers in each treatment cohort per 1,000 person-years versus the matched population) were 2.43 (95% CI: 1.92; 2.94) for the naive cohort; 3.14 (95% CI: 2.50; 3.78) for thiopurine-treated, 2.42 (95% CI: 1.63; 3.22) for TNFi-treated, 2.59 (95% CI: 1.53; 3.64) for thiopurine + TNFi, 2.61 (95% CI: −0.08; 5.30) for vedolizumab, and 1.54 (95% CI: −1.34; 4.41) for ustekinumab. The excess cancer incidence was primarily because of nonmelanoma skin cancer (squamous cell and basal cell carcinoma). After exclusion of nonmelanoma skin cancers, the excess overall cancer incidence was 1.27 to 0.96 cases/1,000 person-years in the naïve, thiopurine, and TNFi-treated groups, but not significantly increased in the other. IR differences for overall cancer increased and hazard ratios decreased with increasing patient age. DISCUSSION: Elevated overall cancer incidence was observed across all treatment cohorts, also in treatment-naïve patients. After exclusion of nonmelanoma skin cancer, the excess cancer incidence in CD was around 1 extra case per 1,000 person-years because of lung, small bowel, hepatobiliary, and hematologic cancers.
- 26 August 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Open AccessAbsolute Risk of Malignancy by Treatment in Patients With Crohn's Disease Compared with the General Population: A Nationwide Population-Based Cohort Study
INTRODUCTION: Real-world data quantifying absolute cancer risk in Crohn's disease (CD) by treatment status are lacking but are essential for patient counselling. METHODS: We linked nationwide Swedish register data and assessed incident cancers overall and by type in patients with CD 2007–2023. We estimated age-stratified incidence rate (IR) differences compared with the general population in a once-exposed-always-exposed design. Treatment cohorts comprised new users of thiopurine, tumor necrosis factor inhibitors (TNFi), thiopurine + TNFi, vedolizumab, ustekinumab, and patients naïve to immunomodulatory drugs. RESULTS: We followed 38,733 patients and 360,616 comparator subjects for a median 7.3 years. The IR differences for any cancer (number of excess cancers in each treatment cohort per 1,000 person-years versus the matched population) were 2.43 (95% CI: 1.92; 2.94) for the naive cohort; 3.14 (95% CI: 2.50; 3.78) for thiopurine-treated, 2.42 (95% CI: 1.63; 3.22) for TNFi-treated, 2.59 (95% CI: 1.53; 3.64) for thiopurine + TNFi, 2.61 (95% CI: −0.08; 5.30) for vedolizumab, and 1.54 (95% CI: −1.34; 4.41) for ustekinumab. The excess cancer incidence was primarily because of nonmelanoma skin cancer (squamous cell and basal cell carcinoma). After exclusion of nonmelanoma skin cancers, the excess overall cancer incidence was 1.27 to 0.96 cases/1,000 person-years in the naïve, thiopurine, and TNFi-treated groups, but not significantly increased in the other. IR differences for overall cancer increased and hazard ratios decreased with increasing patient age. DISCUSSION: Elevated overall cancer incidence was observed across all treatment cohorts, also in treatment-naïve patients. After exclusion of nonmelanoma skin cancer, the excess cancer incidence in CD was around 1 extra case per 1,000 person-years because of lung, small bowel, hepatobiliary, and hematologic cancers.
- Open Access
Trends in Corticosteroid Use and Excess in Patients With Inflammatory Bowel Disease in the United States, Sweden, and Denmark
Background and Aims: Studies show that corticosteroid use in inflammatory bowel disease (IBD) exceeds guideline recommendations. To better understand patterns of corticosteroid use and identify factors associated with excess exposure, we examined long‐term trends in corticosteroid prescribing practices in large IBD populations across 3 countries. Methods: This retrospective analysis used data from US administrative claims (2007–2018) and national registries from Sweden (2006–2022) and Denmark (1995–2018). The prevalent cohort included patients with ≥ 2 records of an IBD diagnosis since data collection. The incident cohort included patients with a new IBD diagnosis. Excess corticosteroid use was defined as ≥ 2 separate corticosteroid courses within 1 year and/or continuous corticosteroid exposure ≥ 3 months. We conducted multivariable logistic regression to identify variables associated with excess use. Results: In prevalent cohorts, including 257,359 (United States), 75,301 (Sweden), and 46,785 (Denmark) patients, annual rates of corticosteroid use and excess declined over the study period in the United States (use: CD [28.1 → 26.4%], UC [31.6 → 27.5%]; excess: CD [13.7 → 11.3%], UC [16.9% → 11.8%]), Sweden (use: CD [29.8% → 20.9%], UC [21.5% → 14.8%]; excess: CD [22.8% → 15.2%], UC [14.8% → 9.5%]), and Denmark (use: CD [15.5% → 10.0%], UC [12.1% → 8.5%]; excess: CD [6.8% → 3.2%], UC [4.9% → 2.5%]). In incident cohorts, including 106,845 (United States), 45,347 (Sweden), and 37,681 (Denmark) patients, corticosteroid use and excess were highest during the first year post‐diagnosis. During years 2‐4 post‐diagnosis, IBD complications, IBD‐related hospitalizations, and previous advanced therapy exposure (excluding CD Danish cohort) were associated with excess use. Conclusions: Corticosteroid use decreased over time, though exposure varied across countries. Corticosteroid use and excess were highest during the first year after diagnosis.
Open AccessTrends in Corticosteroid Use and Excess in Patients With Inflammatory Bowel Disease in the United States, Sweden, and Denmark
Background and Aims: Studies show that corticosteroid use in inflammatory bowel disease (IBD) exceeds guideline recommendations. To better understand patterns of corticosteroid use and identify factors associated with excess exposure, we examined long‐term trends in corticosteroid prescribing practices in large IBD populations across 3 countries. Methods: This retrospective analysis used data from US administrative claims (2007–2018) and national registries from Sweden (2006–2022) and Denmark (1995–2018). The prevalent cohort included patients with ≥ 2 records of an IBD diagnosis since data collection. The incident cohort included patients with a new IBD diagnosis. Excess corticosteroid use was defined as ≥ 2 separate corticosteroid courses within 1 year and/or continuous corticosteroid exposure ≥ 3 months. We conducted multivariable logistic regression to identify variables associated with excess use. Results: In prevalent cohorts, including 257,359 (United States), 75,301 (Sweden), and 46,785 (Denmark) patients, annual rates of corticosteroid use and excess declined over the study period in the United States (use: CD [28.1 → 26.4%], UC [31.6 → 27.5%]; excess: CD [13.7 → 11.3%], UC [16.9% → 11.8%]), Sweden (use: CD [29.8% → 20.9%], UC [21.5% → 14.8%]; excess: CD [22.8% → 15.2%], UC [14.8% → 9.5%]), and Denmark (use: CD [15.5% → 10.0%], UC [12.1% → 8.5%]; excess: CD [6.8% → 3.2%], UC [4.9% → 2.5%]). In incident cohorts, including 106,845 (United States), 45,347 (Sweden), and 37,681 (Denmark) patients, corticosteroid use and excess were highest during the first year post‐diagnosis. During years 2‐4 post‐diagnosis, IBD complications, IBD‐related hospitalizations, and previous advanced therapy exposure (excluding CD Danish cohort) were associated with excess use. Conclusions: Corticosteroid use decreased over time, though exposure varied across countries. Corticosteroid use and excess were highest during the first year after diagnosis.
- Open Access
- 30 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (6) , e1562-e1572
Work Loss and Income Before and After Diagnosis of Addison's Disease: A Population-Based Longitudinal Study
Context: The effect of autoimmune Addison's disease (AAD) on work ability and income over time remains unclear. Objective: This work aimed to evaluate differences and temporal trends in income and lost workdays among patients with AAD before and after diagnosis, vs matched general population comparators. This nationwide, register-based cohort study was conducted in Sweden. We linked the Swedish Addison Register with national health registers to identify 716 working-age individuals (aged 20-62 years) with incident AAD 2003 to 2019 and 3271 general-population comparators matched by sex, age, county, calendar year, and education level. Annual work loss, taxable earnings, and disposable income were examined over a 10-year period around diagnosis using linear (work loss) and quantile (earnings, income) regression. Results: Patients with AAD had significantly more work loss than comparators from 1 year before to 3 years after diagnosis, with the largest difference the year after diagnosis (mean difference: 30.5 days; 95% CI, 22.9-38.0 days). Median taxable earnings were lower in patients with AAD 1 year before (median difference: $−1107; 95% CI, $−2042 to $−173; P = .02) and 1 year after diagnosis ($−1105; 95% CI, $−2166 to $−43; P = .04). Disposable income was also reduced 1 year after diagnosis (median difference: $−1084; 95% CI, $−1813 to $−354; P = .004). Conclusion: In AAD, increased work loss and reduced earnings and income were concentrated around diagnosis, peaking in the year after. Reassuringly, both absence from work and income normalized within 4 years following diagnosis.
- 30 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (6) , e1562-e1572
Open AccessWork Loss and Income Before and After Diagnosis of Addison's Disease: A Population-Based Longitudinal Study
Context: The effect of autoimmune Addison's disease (AAD) on work ability and income over time remains unclear. Objective: This work aimed to evaluate differences and temporal trends in income and lost workdays among patients with AAD before and after diagnosis, vs matched general population comparators. This nationwide, register-based cohort study was conducted in Sweden. We linked the Swedish Addison Register with national health registers to identify 716 working-age individuals (aged 20-62 years) with incident AAD 2003 to 2019 and 3271 general-population comparators matched by sex, age, county, calendar year, and education level. Annual work loss, taxable earnings, and disposable income were examined over a 10-year period around diagnosis using linear (work loss) and quantile (earnings, income) regression. Results: Patients with AAD had significantly more work loss than comparators from 1 year before to 3 years after diagnosis, with the largest difference the year after diagnosis (mean difference: 30.5 days; 95% CI, 22.9-38.0 days). Median taxable earnings were lower in patients with AAD 1 year before (median difference: $−1107; 95% CI, $−2042 to $−173; P = .02) and 1 year after diagnosis ($−1105; 95% CI, $−2166 to $−43; P = .04). Disposable income was also reduced 1 year after diagnosis (median difference: $−1084; 95% CI, $−1813 to $−354; P = .004). Conclusion: In AAD, increased work loss and reduced earnings and income were concentrated around diagnosis, peaking in the year after. Reassuringly, both absence from work and income normalized within 4 years following diagnosis.
- 15 December 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (2)
Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: a nationwide cohort study
Background: We aimed to assess the risk of serious infections in patients with inflammatory bowel disease (IBD) exposed to different advanced therapies. Methods: We linked nationwide registers and compared rates of incident serious infections in patients with Crohn’s disease (CD) and ulcerative colitis (UC) exposed to medical therapies versus matched general population comparators during 2007-2023. We 1:1 propensity score-matched individuals with IBD to compare infection risk across therapies. Results: We identified 55 866 patients with IBD naïve to immunomodulators (IMM) and advanced therapies, 20 392 exposed to IMM, 15 973 to anti-tumor necrosis factor (anti-TNF), 9035 to IMM with anti-TNF, 3948 to vedolizumab, 2926 to ustekinumab, 659 to tofacitinib, 987 to upadacitinib, 262 to filgotinib, and 163 to risankizumab with 987 366 matched comparators with up to 18 years of follow-up. Compared to the general population (incidence rate range 0.39-1.13 per 100 person-years [PY]), patients with IBD had a higher incidence of serious infections (naïve 2.31 per 100 PY; adjusted hazard ratio [aHR] 1.89, 95% confidence interval [CI] 1.84-1.94), IMM 3.27 per 100 PY (aHR 4.45, 95% CI 4.24-4.66), and advanced therapies 3.14-8.10 per 100 PY (aHR 3.45-10.55, 95% CI 3.04-26.65). Relative risks were elevated in the pediatric population, and for opportunistic and gastrointestinal infections. No differences in infection rates were observed in propensity score-matched comparisons of different advanced therapies. Conclusion: Patients with IBD were at an increased risk of infections, even among those naïve to IMM and advanced therapies. There was no significant difference in the risk of infections across advanced therapy exposures.
- 15 December 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (2)
Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: a nationwide cohort study
Background: We aimed to assess the risk of serious infections in patients with inflammatory bowel disease (IBD) exposed to different advanced therapies. Methods: We linked nationwide registers and compared rates of incident serious infections in patients with Crohn’s disease (CD) and ulcerative colitis (UC) exposed to medical therapies versus matched general population comparators during 2007-2023. We 1:1 propensity score-matched individuals with IBD to compare infection risk across therapies. Results: We identified 55 866 patients with IBD naïve to immunomodulators (IMM) and advanced therapies, 20 392 exposed to IMM, 15 973 to anti-tumor necrosis factor (anti-TNF), 9035 to IMM with anti-TNF, 3948 to vedolizumab, 2926 to ustekinumab, 659 to tofacitinib, 987 to upadacitinib, 262 to filgotinib, and 163 to risankizumab with 987 366 matched comparators with up to 18 years of follow-up. Compared to the general population (incidence rate range 0.39-1.13 per 100 person-years [PY]), patients with IBD had a higher incidence of serious infections (naïve 2.31 per 100 PY; adjusted hazard ratio [aHR] 1.89, 95% confidence interval [CI] 1.84-1.94), IMM 3.27 per 100 PY (aHR 4.45, 95% CI 4.24-4.66), and advanced therapies 3.14-8.10 per 100 PY (aHR 3.45-10.55, 95% CI 3.04-26.65). Relative risks were elevated in the pediatric population, and for opportunistic and gastrointestinal infections. No differences in infection rates were observed in propensity score-matched comparisons of different advanced therapies. Conclusion: Patients with IBD were at an increased risk of infections, even among those naïve to IMM and advanced therapies. There was no significant difference in the risk of infections across advanced therapy exposures.
- Open Access
- 16 June 2025
- Vol. 18
Prospective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase.
Tofacitinib is a Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Prospective real-world data are scarce. To collect data on clinical outcomes, including health-related quality of life (HRQoL) and fatigue during treatment with tofacitinib. This is a prospective observational multicentre study in Sweden. In this analysis, outcomes at weeks 2, 8 and 16 are reported. Patients with active UC confirmed with endoscopy or faecal calprotectin (FC) were enrolled during 2020-2023 when starting tofacitinib therapy. In total, 103 patients were included. After 2 weeks of treatment, 50% (39/78) had achieved symptomatic response and at week 16, 39% (35/89) had achieved corticosteroid-free clinical remission according to the partial Mayo score. At week 16, a reduction in FC by ⩾50% was seen in 49% (35/71) and 24% (11/46) were in endoscopic remission. The frequency of arthralgia decreased from 29% (30/103) at baseline to 11% (10/89) at week 16. Regarding HRQoL at week 16; each of the four Short Health Scale dimensions (symptoms, social function, disease-related worry and general well-being) had improved by a median of 1 point (p < 0.01) and the European Quality of Life 5 Dimensions 5 Levels index improved from 0.80 to 0.87. Finally, the Inflammatory Bowel Disease Fatigue score measuring occurrence and severity showed an improvement with a decrease from 9 points at baseline to 6 at week 16 (p < 0.05). Induction therapy with tofacitinib therapy was associated with improvements in patient-reported outcome measures of symptoms, endoscopic activity, arthralgia, HRQoL and fatigue. These real-world data illustrate that tofacitinib is a fast-acting drug with broad therapeutic effects in UC. NCT04338204.
- 16 June 2025
- Vol. 18
Open AccessProspective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase.
Tofacitinib is a Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Prospective real-world data are scarce. To collect data on clinical outcomes, including health-related quality of life (HRQoL) and fatigue during treatment with tofacitinib. This is a prospective observational multicentre study in Sweden. In this analysis, outcomes at weeks 2, 8 and 16 are reported. Patients with active UC confirmed with endoscopy or faecal calprotectin (FC) were enrolled during 2020-2023 when starting tofacitinib therapy. In total, 103 patients were included. After 2 weeks of treatment, 50% (39/78) had achieved symptomatic response and at week 16, 39% (35/89) had achieved corticosteroid-free clinical remission according to the partial Mayo score. At week 16, a reduction in FC by ⩾50% was seen in 49% (35/71) and 24% (11/46) were in endoscopic remission. The frequency of arthralgia decreased from 29% (30/103) at baseline to 11% (10/89) at week 16. Regarding HRQoL at week 16; each of the four Short Health Scale dimensions (symptoms, social function, disease-related worry and general well-being) had improved by a median of 1 point (p < 0.01) and the European Quality of Life 5 Dimensions 5 Levels index improved from 0.80 to 0.87. Finally, the Inflammatory Bowel Disease Fatigue score measuring occurrence and severity showed an improvement with a decrease from 9 points at baseline to 6 at week 16 (p < 0.05). Induction therapy with tofacitinib therapy was associated with improvements in patient-reported outcome measures of symptoms, endoscopic activity, arthralgia, HRQoL and fatigue. These real-world data illustrate that tofacitinib is a fast-acting drug with broad therapeutic effects in UC. NCT04338204.
- Open Access
- 29 November 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (S8) , S73-S84
Stillbirths: Contribution of preterm birth and size‐for‐gestational age for 125.4 million total births from nationwide records in 13 countries, 2000–2020
Objective: To examine the contribution of preterm birth and size‐for‐gestational age in stillbirths using six ‘newborn types’. Design: Population‐based multi‐country analyses. Setting: Births collected through routine data systems in 13 countries. Sample: 125 419 255 total births from 22 +0 to 44 +6 weeks’ gestation identified from 2000 to 2020. Methods: We included 635 107 stillbirths from 22 +0 weeks’ gestation from 13 countries. We classified all births, including stillbirths, into six ‘newborn types’ based on gestational age information (preterm, PT, +0 weeks versus term, T, ≥37 +0 weeks) and size‐for‐gestational age defined as small (SGA, 90th centile) for gestational age, according to the international newborn size for gestational age and sex INTERGROWTH‐21st standards. Main outcome measures: Distribution of stillbirths, stillbirth rates and rate ratios according to six newborn types. Results: 635 107 (0.5%) of the 125 419 255 total births resulted in stillbirth after 22 +0 weeks. Most stillbirths (74.3%) were preterm. Around 21.2% were SGA types (PT + SGA [16.2%], PT + AGA [48.3%], T + SGA [5.0%]) and 14.1% were LGA types (PT + LGA [9.9%], T + LGA [4.2%]). The median rate ratio (RR) for stillbirth was highest in PT + SGA babies (RR 81.1, interquartile range [IQR], 68.8–118.8) followed by PT + AGA (RR 25.0, IQR, 20.0–34.3), PT + LGA (RR 25.9, IQR, 13.8–28.7) and T + SGA (RR 5.6, IQR, 5.1–6.0) compared with T + AGA. Stillbirth rate ratios were similar for T + LGA versus T + AGA (RR 0.7, IQR, 0.7–1.1). At the population level, 25% of stillbirths were attributable to small‐for‐gestational‐age. Conclusions: In these high‐quality data from high/middle income countries, almost three‐quarters of stillbirths were born preterm and a fifth small‐for‐gestational age, with the highest stillbirth rates associated with the coexistence of preterm and SGA. Further analyses are needed to better understand patterns of gestation‐specific risk in these populations, as well as patterns in lower‐income contexts, especially those with higher rates of intrapartum stillbirth and SGA.
- 29 November 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (S8) , S73-S84
Open AccessStillbirths: Contribution of preterm birth and size‐for‐gestational age for 125.4 million total births from nationwide records in 13 countries, 2000–2020
Objective: To examine the contribution of preterm birth and size‐for‐gestational age in stillbirths using six ‘newborn types’. Design: Population‐based multi‐country analyses. Setting: Births collected through routine data systems in 13 countries. Sample: 125 419 255 total births from 22 +0 to 44 +6 weeks’ gestation identified from 2000 to 2020. Methods: We included 635 107 stillbirths from 22 +0 weeks’ gestation from 13 countries. We classified all births, including stillbirths, into six ‘newborn types’ based on gestational age information (preterm, PT, +0 weeks versus term, T, ≥37 +0 weeks) and size‐for‐gestational age defined as small (SGA, 90th centile) for gestational age, according to the international newborn size for gestational age and sex INTERGROWTH‐21st standards. Main outcome measures: Distribution of stillbirths, stillbirth rates and rate ratios according to six newborn types. Results: 635 107 (0.5%) of the 125 419 255 total births resulted in stillbirth after 22 +0 weeks. Most stillbirths (74.3%) were preterm. Around 21.2% were SGA types (PT + SGA [16.2%], PT + AGA [48.3%], T + SGA [5.0%]) and 14.1% were LGA types (PT + LGA [9.9%], T + LGA [4.2%]). The median rate ratio (RR) for stillbirth was highest in PT + SGA babies (RR 81.1, interquartile range [IQR], 68.8–118.8) followed by PT + AGA (RR 25.0, IQR, 20.0–34.3), PT + LGA (RR 25.9, IQR, 13.8–28.7) and T + SGA (RR 5.6, IQR, 5.1–6.0) compared with T + AGA. Stillbirth rate ratios were similar for T + LGA versus T + AGA (RR 0.7, IQR, 0.7–1.1). At the population level, 25% of stillbirths were attributable to small‐for‐gestational‐age. Conclusions: In these high‐quality data from high/middle income countries, almost three‐quarters of stillbirths were born preterm and a fifth small‐for‐gestational age, with the highest stillbirth rates associated with the coexistence of preterm and SGA. Further analyses are needed to better understand patterns of gestation‐specific risk in these populations, as well as patterns in lower‐income contexts, especially those with higher rates of intrapartum stillbirth and SGA.
- Open Access
- 27 November 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (S8) , S109-S120
Neonatal mortality risk of large‐for‐gestational‐age and macrosomic live births in 15 countries, including 115.6 million nationwide linked records, 2000–2020
Objective: We aimed to compare the prevalence and neonatal mortality associated with large for gestational age (LGA) and macrosomia among 115.6 million live births in 15 countries, between 2000 and 2020. Design: Population‐based, multi‐country study. Setting: National healthcare systems. Population: Liveborn infants. Methods: We used individual‐level data identified for the Vulnerable Newborn Measurement Collaboration. We calculated the prevalence and relative risk (RR) of neonatal mortality among live births born at term + LGA (>90th centile, and also >95th and >97th centiles when the data were available) versus term + appropriate for gestational age (AGA, 10th–90th centiles) and macrosomic (≥4000, ≥4500 and ≥5000 g, regardless of gestational age) versus 2500–3999 g. INTERGROWTH 21st served as the reference population. Main outcome measures: Prevalence and neonatal mortality risks. Results: Large for gestational age was common (median prevalence 18.2%; interquartile range, IQR, 13.5%–22.0%), and overall was associated with a lower neonatal mortality risk compared with AGA (RR 0.83, 95% CI 0.77–0.89). Around one in ten babies were ≥4000 g (median prevalence 9.6% (IQR 6.4%–13.3%), with 1.2% (IQR 0.7%–2.0%) ≥4500 g and with 0.2% (IQR 0.1%–0.2%) ≥5000 g). Overall, macrosomia of ≥4000 g was not associated with increased neonatal mortality risk (RR 0.80, 95% CI 0.69–0.94); however, a higher risk was observed for birthweights of ≥4500 g (RR 1.52, 95% CI 1.10–2.11) and ≥5000 g (RR 4.54, 95% CI 2.58–7.99), compared with birthweights of 2500–3999 g, with the highest risk observed in the first 7 days of life. Conclusions: In this population, birthweight of ≥4500 g was the most useful marker for early mortality risk in big babies and could be used to guide clinical management decisions.
- 27 November 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (S8) , S109-S120
Open AccessNeonatal mortality risk of large‐for‐gestational‐age and macrosomic live births in 15 countries, including 115.6 million nationwide linked records, 2000–2020
Objective: We aimed to compare the prevalence and neonatal mortality associated with large for gestational age (LGA) and macrosomia among 115.6 million live births in 15 countries, between 2000 and 2020. Design: Population‐based, multi‐country study. Setting: National healthcare systems. Population: Liveborn infants. Methods: We used individual‐level data identified for the Vulnerable Newborn Measurement Collaboration. We calculated the prevalence and relative risk (RR) of neonatal mortality among live births born at term + LGA (>90th centile, and also >95th and >97th centiles when the data were available) versus term + appropriate for gestational age (AGA, 10th–90th centiles) and macrosomic (≥4000, ≥4500 and ≥5000 g, regardless of gestational age) versus 2500–3999 g. INTERGROWTH 21st served as the reference population. Main outcome measures: Prevalence and neonatal mortality risks. Results: Large for gestational age was common (median prevalence 18.2%; interquartile range, IQR, 13.5%–22.0%), and overall was associated with a lower neonatal mortality risk compared with AGA (RR 0.83, 95% CI 0.77–0.89). Around one in ten babies were ≥4000 g (median prevalence 9.6% (IQR 6.4%–13.3%), with 1.2% (IQR 0.7%–2.0%) ≥4500 g and with 0.2% (IQR 0.1%–0.2%) ≥5000 g). Overall, macrosomia of ≥4000 g was not associated with increased neonatal mortality risk (RR 0.80, 95% CI 0.69–0.94); however, a higher risk was observed for birthweights of ≥4500 g (RR 1.52, 95% CI 1.10–2.11) and ≥5000 g (RR 4.54, 95% CI 2.58–7.99), compared with birthweights of 2500–3999 g, with the highest risk observed in the first 7 days of life. Conclusions: In this population, birthweight of ≥4500 g was the most useful marker for early mortality risk in big babies and could be used to guide clinical management decisions.